Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors

References

• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008;20:1–12.
   PubMed Web of Science ®Google Scholar
• Bergestuen DS, Aabakken L, Holm K, Vatn M. Thiis-Evensen E: Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol 2009;44:1084–91.
   PubMed Web of Science ®Google Scholar
• Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–90.
   PubMed Web of Science ®Google Scholar
• Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997;79:1086–93.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717–51.
   PubMed Web of Science ®Google Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983;1:727–40.
   PubMed Web of Science ®Google Scholar
• Frojd C, Larsson G, Lampic C, von EL. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes 2007;5:18.
   PubMed Web of Science ®Google Scholar
• von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993;329:1073–8.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663–6.
   PubMed Web of Science ®Google Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225–9.
   PubMed Web of Science ®Google Scholar
• O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770–6.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 2009;27:4656–63.
   PubMed Web of Science ®Google Scholar
• Saslow SB, O'Brien MD, Camilleri M, von der OM, Homburger HA, Klee GG, Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Am J Gastroenterol 1997;92:2250–6.
   PubMed Web of Science ®Google Scholar
• Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13–27.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, De Herder WW, Feelders RA, Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62.
   PubMed Web of Science ®Google Scholar
• Abrahamsson H, Antov S, Bosaeus I. Gastrointestinal and colonic segmental transit time evaluated by a single abdominal x-ray in healthy subjects and constipated patients. Scand J Gastroenterol Suppl 1988;152:72–80.
   PubMedGoogle Scholar
• Schlageter V, Drljaca P, Popovic PS, Kucera P. A magnetic tracking system based on highly sensitive integrated hall sensors. JSME Int J Ser C 2002;45:967–73.
   Web of Science ®Google Scholar
• Stathopoulos E, Schlageter V, Meyrat B, Ribaupierre Y, Kucera P. Magnetic pill tracking: a novel non-invasive tool for investigation of human digestive motility. Neurogastroenterol Motil 2005;17:148–54.
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127–30.
   PubMed Web of Science ®Google Scholar
• Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49:740–56.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707–16.
   PubMed Web of Science ®Google Scholar
• Hansen MB, Arif F, Gregersen H, Bruusgaard H, Wallin L. Effect of serotonin on small intestinal contractility in healthy volunteers. Physiol Res 2008;57:63–71.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Shiihara Y, Shiba Y, Sano I, Sakai T, Mizumoto A, Itoh Z. Effect of 5-hydroxytryptamine on gastrointestinal motility in conscious guinea-pigs. Neurogastroenterol Motil 1997;9:205–14.
   PubMed Web of Science ®Google Scholar
• Budhoo MR, Kellum JM. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res 1994;57:44–8.
   PubMed Web of Science ®Google Scholar
• Lordal M, Hellstrom PM. Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil 1999;11:1–10.
   PubMed Web of Science ®Google Scholar
• Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007;19(Suppl 2):25–31.
   PubMedGoogle Scholar
• Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005;30:611–22.
   PubMed Web of Science ®Google Scholar
• Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology 1987;92:40–7.
   PubMed Web of Science ®Google Scholar
• Chan YK, Kwan AC, Yuen H, Yeung YW, Lai KC, Wu J, Normal colon transit time in healthy Chinese adults in Hong Kong. J Gastroenterol Hepatol 2004;19:1270–5.
   PubMed Web of Science ®Google Scholar